63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details
臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05338190 (ClinicalTrials.gov) | June 1, 2022 | 21/3/2022 | Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia | A Phase 3 Randomized and Double-blind Controlled Trial Comparing the Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition to Rituximab in Adult Patients With Persistent or Chronic Immune Thrombocytopenia (ITP) | Primary Immune Thrombocytopenia (ITP) | Drug: Combination of Rituximab with subcutaneous belimumab;Drug: Combination of Rituximab with subcutaneous placebo | Assistance Publique - Hôpitaux de Paris | GlaxoSmithKline | Not yet recruiting | 18 Years | N/A | All | 132 | Phase 3 | NULL |
2 | ChiCTR2200058433 | 2022-04-11 | 2022-04-09 | Belimumab in combination with cyclosporine for corticosteroid-refractory primary immune thrombocytopenia in adults | Efficacy and safety of belliumab in combination with cyclosporine in adults with persistent or chronic corticosteroid-refractory primary immune thrombocytopenia: a single-arm, open, multicenter clinical study | Primary immune thrombocytopenia | Group 1:belimumab and cyclosporine; | The Second Affiliated Hospital of Kunming Medical University | NULL | Pending | Both | Group 1:37; | China |